Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CytomX Therapeutics, Inc.CTMX · Entity 5124 | Director · CEO | March 17, 2026 | March 19, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CytomX Therapeutics, Inc.
Report date March 17, 2026 · Filed March 19, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,078,922 |
Reported balance
After 2026-03-17 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-03-17 · Sale · Disposed 118,969 · Balance 1,078,922 F1: The shares were sold solely to satisfy tax or other government withholding obligations in connection with the vesting of restricted stock units ("RSUs"). F2: Includes 457,500 RSUs. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 93,158 |
Reported balance
Holding disclosure · report date 2026-03-17 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 93,158 F3: Shares held by Sean A. McCarthy 2018 Trust, of which Reporting Person is trustee. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares were sold solely to satisfy tax or other government withholding obligations in connection with the vesting of restricted stock units ("RSUs").
F2: Includes 457,500 RSUs.
F3: Shares held by Sean A. McCarthy 2018 Trust, of which Reporting Person is trustee.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 26, 2017 Filed Jun 27, 2017 20:55 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | Exercise / conversionCommon Stock | 4,481 | $0.95 | $4,234.55 |
DisclosureSEC source: 0001140361-17-026273 · doc1.xml · nonDerivative · entry 1 McCarthy Sean A. · CIK 0001654058 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,726 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 05, 2017 Filed Jun 6, 2017 21:57 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | Exercise / conversionStock Option (right to buy) · Derivative | 300 | $0.00 Strike: $0.95 | $0.00 |
DisclosureSEC source: 0001140361-17-024051 · doc1.xml · derivative · entry 4 McCarthy Sean A. · CIK 0001654058 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,772 Underlying: Common Stock · 300 shares Expires 2023-02-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 100% of the shares subject to the option are fully vested and exercisable. Read SEC document |
| June 05, 2017 Filed Jun 6, 2017 21:57 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | SaleCommon Stock | 300 | $15.00 | $4,500.00 |
DisclosureSEC source: 0001140361-17-024051 · doc1.xml · nonDerivative · entry 2 McCarthy Sean A. · CIK 0001654058 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,245 F1 · kind: The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. Read SEC document |
| June 05, 2017 Filed Jun 6, 2017 21:57 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | Exercise / conversionCommon Stock | 300 | $0.95 | $283.50 |
DisclosureSEC source: 0001140361-17-024051 · doc1.xml · nonDerivative · entry 1 McCarthy Sean A. · CIK 0001654058 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,545 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 31, 2017 Filed Jun 2, 2017 19:40 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | GrantCommon Stock | 2,266 | $8.68 | $19,665.48 |
DisclosureSEC source: 0001140361-17-023529 · doc1.xml · nonDerivative · entry 1 McCarthy Sean A. · CIK 0001654058 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,245 F1 · kind: 2,266 shares were acquired pursuant to the Issuer's Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| May 01, 2017 Filed May 2, 2017 22:11 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | Exercise / conversionStock Option (right to buy) · Derivative | 4,781 | $0.00 Strike: $0.95 | $0.00 |
DisclosureSEC source: 0001140361-17-017962 · doc1.xml · derivative · entry 4 McCarthy Sean A. · CIK 0001654058 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,072 Underlying: Common Stock · 4,781 shares Expires 2023-02-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: 100% of the shares subject to the option are fully vested and exercisable. Read SEC document |
| May 01, 2017 Filed May 2, 2017 22:11 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | SaleCommon Stock | 4,781 | $15.70 | $75,061.70 |
DisclosureSEC source: 0001140361-17-017962 · doc1.xml · nonDerivative · entry 2 McCarthy Sean A. · CIK 0001654058 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,979 F1 · kind: The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $15.60 to $15.76, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| May 01, 2017 Filed May 2, 2017 22:11 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | Exercise / conversionCommon Stock | 4,781 | $0.95 | $4,518.05 |
DisclosureSEC source: 0001140361-17-017962 · doc1.xml · nonDerivative · entry 1 McCarthy Sean A. · CIK 0001654058 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,760 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 04, 2017 Filed Apr 5, 2017 16:18 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | Exercise / conversionStock Option (right to buy) · Derivative | 4,781 | $0.00 Strike: $0.95 | $0.00 |
DisclosureSEC source: 0001140361-17-014775 · doc1.xml · derivative · entry 7 McCarthy Sean A. · CIK 0001654058 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,853 Underlying: Common Stock · 4,781 shares Expires 2023-02-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: 100% of the shares subject to the option are fully vested and exercisable. Read SEC document |
| April 04, 2017 Filed Apr 5, 2017 16:18 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | SaleCommon Stock | 4,781 | $17.50 | $83,667.50 |
DisclosureSEC source: 0001140361-17-014775 · doc1.xml · nonDerivative · entry 4 McCarthy Sean A. · CIK 0001654058 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,979 F1 · kind: The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. Read SEC document |
| April 04, 2017 Filed Apr 5, 2017 16:18 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | Exercise / conversionCommon Stock | 4,781 | $0.95 | $4,518.05 |
DisclosureSEC source: 0001140361-17-014775 · doc1.xml · nonDerivative · entry 3 McCarthy Sean A. · CIK 0001654058 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,760 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 03, 2017 Filed Apr 5, 2017 16:18 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | Exercise / conversionStock Option (right to buy) · Derivative | 4,781 | $0.00 Strike: $0.95 | $0.00 |
DisclosureSEC source: 0001140361-17-014775 · doc1.xml · derivative · entry 6 McCarthy Sean A. · CIK 0001654058 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,634 Underlying: Common Stock · 4,781 shares Expires 2023-02-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: 100% of the shares subject to the option are fully vested and exercisable. Read SEC document |
| April 03, 2017 Filed Apr 5, 2017 16:18 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | SaleCommon Stock | 4,781 | $16.94 | $80,990.14 |
DisclosureSEC source: 0001140361-17-014775 · doc1.xml · nonDerivative · entry 2 McCarthy Sean A. · CIK 0001654058 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,979 F1 · kind: The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $16.71 to $17.26, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| April 03, 2017 Filed Apr 5, 2017 16:18 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | Exercise / conversionCommon Stock | 4,781 | $0.95 | $4,518.05 |
DisclosureSEC source: 0001140361-17-014775 · doc1.xml · nonDerivative · entry 1 McCarthy Sean A. · CIK 0001654058 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,760 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 20, 2017 Filed Mar 21, 2017 22:04 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | Exercise / conversionStock Option (Right to Buy) · Derivative | 14,343 | $0.00 Strike: $0.95 | $0.00 |
DisclosureSEC source: 0001140361-17-012869 · doc1.xml · derivative · entry 4 McCarthy Sean A. · CIK 0001654058 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,415 Underlying: Common Stock · 14,343 shares Expires 2023-02-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 100% of the shares subject to the option are fully vested and exercisable. Read SEC document |
| March 20, 2017 Filed Mar 21, 2017 22:04 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | SaleCommon Stock | 14,343 | $19.60 | $281,122.80 |
DisclosureSEC source: 0001140361-17-012869 · doc1.xml · nonDerivative · entry 2 McCarthy Sean A. · CIK 0001654058 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,979 F1 · kind: The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. Read SEC document |
| March 20, 2017 Filed Mar 21, 2017 22:04 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | Exercise / conversionCommon Stock | 14,343 | $0.95 | $13,554.14 |
DisclosureSEC source: 0001140361-17-012869 · doc1.xml · nonDerivative · entry 1 McCarthy Sean A. · CIK 0001654058 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,322 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 03, 2017 Filed Mar 3, 2017 22:36 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | Exercise / conversionStock Option (Right to Buy) · Derivative | 14,343 | $0.00 Strike: $1.13 | $0.00 |
DisclosureSEC source: 0001140361-17-010608 · doc1.xml · derivative · entry 4 McCarthy Sean A. · CIK 0001654058 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 366,961 Underlying: Common Stock · 14,343 shares Expires 2021-09-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 100% of the shares subject to the option are fully vested and exercisable. Read SEC document |
| March 03, 2017 Filed Mar 3, 2017 22:36 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | SaleCommon Stock | 14,343 | $15.00 | $215,145.00 |
DisclosureSEC source: 0001140361-17-010608 · doc1.xml · nonDerivative · entry 2 McCarthy Sean A. · CIK 0001654058 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,979 F1 · kind: The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. Read SEC document |
| March 03, 2017 Filed Mar 3, 2017 22:36 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | Exercise / conversionCommon Stock | 14,343 | $1.13 | $16,263.53 |
DisclosureSEC source: 0001140361-17-010608 · doc1.xml · nonDerivative · entry 1 McCarthy Sean A. · CIK 0001654058 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,322 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 25, 2017 Filed Jan 27, 2017 18:54 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | GrantStock Option (right to buy) · Derivative | 310,000 | $0.00 Strike: $11.94 | $0.00 |
DisclosureSEC source: 0001140361-17-003160 · doc1.xml · derivative · entry 1 McCarthy Sean A. · CIK 0001654058 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 310,000 Underlying: Common Stock · 310,000 shares Expires 2027-01-24 F1 · derivative.exercise_date: 1/48th of the shares subject to the option vest on each monthly anniversary measured from January 1, 2017 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer through each such date. Read SEC document |
| November 30, 2016 Filed Dec 2, 2016 00:02 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | GrantCommon Stock | 1,979 | $9.10 | $17,999.01 |
DisclosureSEC source: 0001140361-16-088448 · doc1.xml · nonDerivative · entry 1 McCarthy Sean A. · CIK 0001654058 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,979 F1 · kind: 1,979 shares were acquired pursuant to the Issuer's Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| September 26, 2016 Filed Sep 28, 2016 23:14 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | GrantStock Option (Right to Buy) · Derivative | 122,424 | $0.00 Strike: $1.57 | $0.00 |
DisclosureSEC source: 0001140361-16-080948 · doc1.xml · derivative · entry 2 McCarthy Sean A. · CIK 0001654058 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 122,424 Underlying: Common Stock · 122,424 shares Expires 2025-02-08 F2 · derivative.exercise_date: On February 9, 2015, the Reporting Person was granted an option to purchase 122,424 shares of Common Stock, as adjusted for the 1-for-62.997 reverse stock split effected prior to the Issuer's initial public offering, to vest in full upon achievement of a certain performance-based milestone (the "Performance Option"). On September 26, 2016, the performance milestone was achieved resulting in 100% of the Performance Option vesting. Read SEC document |
| September 26, 2016 Filed Sep 28, 2016 23:14 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | GrantStock Option (Right to Buy) · Derivative | 48,379 | $0.00 Strike: $0.95 | $0.00 |
DisclosureSEC source: 0001140361-16-080948 · doc1.xml · derivative · entry 1 McCarthy Sean A. · CIK 0001654058 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,379 Underlying: Common Stock · 48,379 shares Expires 2023-02-25 F1 · derivative.exercise_date: On February 26, 2013, the Reporting Person was granted an option to purchase 96,758 shares of Common Stock, as adjusted for the 1-for-62.997 reverse stock split effected prior to the Issuer's initial public offering, to vest in two equal tranches upon achievement of certain performance-based milestones (the "Performance Option"). 50% of the Performance Option previously vested upon achievement of the first performance milestone. On September 26, 2016, the second performance milestone was achieved resulting in vesting of the remaining 50% of the Performance Option. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.